Serum 14-3-3η level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab

INTRODUCTION: Treat-to-target strategies to achieve low disease activity or clinical remission are key in the treatment of rheumatoid arthritis (RA). 14-3-3η is a joint-derived biomarker that is expressed at significantly higher levels in patients with RA than in healthy subjects, other autoimmune d...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirata, Shintaro, Marotta, Anthony, Gui, Yuan, Hanami, Kentaro, Tanaka, Yoshiya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599751/
https://www.ncbi.nlm.nih.gov/pubmed/26449724
http://dx.doi.org/10.1186/s13075-015-0799-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599751/
https://www.ncbi.nlm.nih.gov/pubmed/26449724
http://dx.doi.org/10.1186/s13075-015-0799-7

Ejemplares similares